-+ 0.00%
-+ 0.00%
-+ 0.00%

Chardan Capital Maintains Buy on Tenaya Therapeutics, Lowers Price Target to $8

Benzinga·12/12/2025 13:10:03
語音播報
Chardan Capital analyst Geulah Livshits maintains Tenaya Therapeutics (NASDAQ:TNYA) with a Buy and lowers the price target from $9 to $8.